IP Verse

Prevention Of Adverse Effects Caused By Cd3 Specific Binding Domains - EP2637670

The patent EP2637670 was granted to Amgen on Mar 13, 2024. The application was originally filed on Oct 27, 2011 under application number EP11788077A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2637670

AMGEN
Application Number
EP11788077A
Filing Date
Oct 27, 2011
Status
Patent Maintained As Amended
Feb 9, 2024
Grant Date
Mar 13, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

LINDIS BIOTECHDec 7, 2017GRAF VON STOSCHADMISSIBLE
F HOFFMANN LA ROCHEDec 1, 2017MEWBURN ELLISADMISSIBLE

Patent Citations (17) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2010EP66207-
DESCRIPTIONEP0623679
DESCRIPTIONWO2004106381
DESCRIPTIONWO2007068354
DESCRIPTIONWO2008119565
DESCRIPTIONWO2008119566
DESCRIPTIONWO2008119567
DESCRIPTIONWO9954440
INTERNATIONAL-SEARCH-REPORTWO2007068354
INTERNATIONAL-SEARCH-REPORTWO2011051307
INTERNATIONAL-SEARCH-REPORTWO9954440
OPPOSITIONUS2007224191
OPPOSITIONWO2006114115
OPPOSITIONWO2007068354
OPPOSITIONWO2011051307
OPPOSITIONWO2012055961
OPPOSITIONWO9954440

Non-Patent Literature (NPL) Citations (29) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- ALLEN SHIH et al., "Role of Corticosteroids in Palliative Care", Journal of Pain & Palliative Care Pharmacotherapy, (20070000), vol. 21, no. 4, pages 69 - 76-
OPPOSITION- ALLEN SHIH et al., "Role of Corticosteroids in Palliative Care", Journal of Pain & Palliative Care Pharmacotherapy, (20070000), vol. 21, no. 4, pages 69 - 76, XP055443261-
OPPOSITION- AMANN M., "Anti-tumor activity, pharmacology and toxicology of EpCAM/ CD 3- bispecific single-chain antibodies", Dissertation, (20090000), XP055443275-
OPPOSITION- CHATENOUD L. et al, "Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome-dosage and kinetics prerequisites", TRANSPLANTATION, (19910200), vol. 51, no. 2, pages 334 - 338, XP055439988-
OPPOSITION- GOEBELER et al., "CD3/CD19 BISPECIFIC BITE (R) ANTIBODY BLINATUMOMAB TREATMENT OF NON-HODGKIN LYMPHOMA (NHL) PATIENTS: 60 mu G/M-2/D BY CONTINUOUS INFUSION IS TOLERABLE AND RESULTS IN DURABLE RESPONSES", HAEMATOLOGICA, (20100610), vol. 95, no. Suppl 2, page 230-
OPPOSITION- GOEBELER et al., "CD3/CD19 BISPECIFIC BITE (R) ANTIBODY BLINATUMOMAB TREATMENT OF NON-HODGKIN LYMPHOMA (NHL) PATIENTS: 60 mu G/M-2/D BY CONTINUOUS INFUSION IS TOLERABLE AND RESULTS IN DURABLE RESPONSES", HAEMATOLOGICA, (20100610), vol. 95, no. Suppl 2, page 230, XP002667641-
OPPOSITION- GOEBELER M. et al., "CD 3/ CD 19 bispecific BITE@ antibody blinatumomab treatment of non-hodgkin lymphoma (NHL) patients: 60 µg/m2/d by continuous infusion is tolerable and results in durable responses", Haematologica - The Hematology Journal, (20100600), vol. 95, no. 2, page 230, XP002667641-
OPPOSITION- KLINGER, MATTHIAS, "Wirkmechanismus des bispezifischen anti- CD 19 x anti- CD 3 BiTE- Antikorpers MT103 in Patienten mit rezidivem indolenten B-Zell-Non-Hodgkin-Lymphom", dissertation (doctor's thesis, (20090000), XP055288098-
OPPOSITION- SUÁREZ JI, "Treatment of acute brain edema", Rev Neurol, (20010201), vol. 32, no. 3, pages 275 - 81, XP055443280-
OPPOSITION- VIARDOT A. et al., "Treatment of patients with non-hodgkin lymphoma (NHL) with CD 19/ CD 3 bispecific antibody blinatumomab (MT103): Double-step dose increase to continuous infusion of 60 µg/m2/d is tolerable and highly effective", Blood, (20100000), vol. 116, no. 21, pages 1186 - 1187-
OPPOSITION- WRIGHT AD et al., "Birmingham Medical Research Expeditionary Society . Medicine at high altitude", Clin Med (Lond, (20061100), vol. 6, no. 6, pages 604 - 608, XP055443294-
OPPOSITION- RUDERMAN NB et al., "USE OF GLUCOCORTICOIDS IN THE PALLIATIVE TREATMENT OF METASTATIC BRAIN TUMORS", Cancer, (19650300), vol. 18, pages 298 - 306, XP055443292
OPPOSITION- HOFFMANN et al., "Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct", INTERNATIONAL JOURNAL OF CANCER, (20050520), vol. 115, no. 1, pages 98 - 104, XP002335808
OPPOSITION- HOFFMANN P et al., "Serial killing of tumor cells by cytotoxic T cells redirected with a CD 19-/ CD 3- bispecific single-chain antibody construct", Int J Cancer, (20050520), vol. 115, no. 1, pages 98 - 104, XP002335808
OPPOSITION- SCHLERETH B. et al, "T-cell activation and B-cell depletion in chimpanzees treatedwith a bispecific anti-CD19/anti-CD3 single-chain antibody construct", Cancer Immunol Immunother, (20060500), vol. 55, pages 503 - 514, XP019333227
OPPOSITION- BRANDL C. et al, "The effect of dexamethasone on polyclonal T cell activationand redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct", Cancer Immunol Immunother, (20070220), vol. 56, no. 10, pages 1551 - 1563, XP019539092
OPPOSITION- BRANDL C et al., "The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD 19/ CD 3-bispecific single-chain antibody construct", Cancer Immunol Immunother, (20070220), vol. 56, no. 10, pages 1551 - 63, XP019539092
OPPOSITION- ROZEN, "Migraine headache immunosuppressant therapy", Current Treatment Options in Neurology, (20020900), vol. 4, no. 5, pages 395 - 401, XP055439993
OPPOSITION- INABA H et al., "Glucocorticoid use in acute lymphoblastic leukaemia", Lancet Oncol, (20101012), vol. 11, no. 11, pages 1096 - 106, XP027457505
OPPOSITION- GRUPP SA et al., "Chimeric antigen receptor- modified T cells for acute lymphoid leukemia", N Engl J Med, (20130418), vol. 368, no. 16, pages 1509 - 1518, XP055169041
OPPOSITION- GUARINO, "EFNS guidelines on management of neurological problems in liver transplantation", European Journal of Neurology, (20060112), vol. 13, no. 1, pages 2 - 9, XP055439997
OPPOSITION- DAVILA ML et al., "Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia", Sci Transl Med, (20140219), vol. 6, no. 224, page 224ra25, XP055234425
OPPOSITION- BURGES A et al., "Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti- CD 3 antibody: a phase I/II study", Clin Cancer Res, (20070701), vol. 13, no. 13, pages 3899 - 905, XP055167636
OPPOSITION- PECES R. et al, "High-Dose Methylprednisolone Inhibits the OKT3-lnducedCytokine-Related Syndrome", Nephron, (19930000), vol. 63, no. 1, page 118, XP055439990
OPPOSITION- JONATHAN E. BENJAMIN et al., "The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia", Therapeutic Advances in Hematology, (20160000), vol. 7, no. 3, pages 142 - 156, XP055443264
OPPOSITION- VIARDOT A. et al., "Treatment of patients with non-hodgkin lymphoma (NHL) with CD 19/ CD 3 bispecific antibody blinatumomab (MT103): Double-step dose increase to continuous infusion of 60 µg/m2/d is tolerable and highly effective", Blood, (20100000), vol. 116, no. 21, pages 1186 - 1187, XP009161648
OPPOSITION- STROHLEIN MA et al., "Induction of anti- tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis", J Exp Clin Cancer Res, (20090214), vol. 28, pages 1 - 10, XP021052973
OPPOSITION- BRESLIN S., "Cytokine-release syndrome: overview and nursing implications", Clinical Journal of Oncology Nursing, (20070000), vol. 11, no. 1 Suppl, pages 37 - 42, XP055440000
OPPOSITION- LEE KJ et al., "Clinical use of blinatumomab for B- cell acute lymphoblastic leukemia in adults", Ther Clin Risk Manag, (20160825), vol. 12, pages 1301 - 1310, XP055443269

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents